Abbott Laboratories is making a significant pivot in its business strategy by acquiring Exact Sciences for $23 billion, targeting the expansive U.S. cancer screening and precision oncology market. This acquisition is part of Abbott's overarching goal to boost growth in high-potential sectors like diabetes and cardiovascular care, despite facing challenges related to share price and market scrutiny. The company has reported continued revenue growth but is battling declining stock performance, leading to a cautious outlook among investors. While Abbott's synergies from the acquisition aim for $100 million by 2028, recent stock downgrades and a drop in share value highlight ongoing market pressures.
Click a month on the chart to update the report below.
%20-%20USA%20-%20UNOCHA.svg&width=160)
